Calithera Biosciences Appoints Blake Wise to Board of Directors
September 21 2017 - 4:05PM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, announced today the
appointment of Blake Wise to the company's Board of Directors.
Mr. Wise currently serves as President and Chief Operating
Officer of Achaogen.
"Blake’s extensive oncology therapeutic marketing and
commercialization experience will be valuable as we advance our
development programs towards potential commercialization," said
Susan Molineaux, PhD, President and Chief Executive Officer.
"We look forward to his guidance during this period of growth
of the company as we work towards creating a new class of drugs
that fight cancer and expand therapeutic options for patients."
Mr. Wise joined Achaogen in 2015 and currently serves as
President and Chief Operating Officer. Prior to joining Achaogen,
Mr. Wise served as Vice President, Cross BioOncology at Genentech,
where he led cross-portfolio oncology initiatives, including key
account management, marketing, managed markets, companion
diagnostics, pipeline commercialization, and long-term oncology
strategy. Mr. Wise also held several other leadership
positions at Genentech including Senior Director, Franchise Head
and Life Cycle Leader of the Lytics franchise and as a Sales
Director in BioOncology, Marketing Director in Cystic Fibrosis and
Immunology, and Interactive Marketing Director. Prior to
joining Genentech, Mr. Wise worked in consumer marketing,
e-commerce and online marketing in leadership positions at Gap,
Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in
Business Economics from University of California, Santa Barbara,
and a Masters of Business Administration degree from University of
California, Berkeley, Haas School of Business.
About Calithera Calithera Biosciences, Inc. is
a clinical-stage pharmaceutical company focused on discovering and
developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of
cancer. Calithera’s lead product candidate, CB-839, is a
potent, selective, reversible and orally bioavailable inhibitor of
glutaminase. CB-839 takes advantage of the pronounced dependency
many cancers have on the nutrient glutamine for growth and
survival. It is currently being evaluated in Phase 2 clinical
trials in combination with standard of care agents. CB-1158
is a first-in-class immuno-oncology metabolic checkpoint inhibitor
targeting arginase, a critical immunosuppressive enzyme responsible
for T-cell suppression by myeloid-derived suppressor cells.
Arginase depletes arginine, a nutrient that is critical for the
activation, growth and survival of the body’s cancer-fighting
immune cells, known as cytotoxic T-cells. CB-1158 is being
developed in collaboration with Incyte Corporation and is currently
in a Phase 1 clinical trial. Calithera is headquartered in
South San Francisco, California. For more information about
Calithera, please visit www.calithera.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
"may," "will," "expect," "anticipate," "estimate," "intend,"
"poised" and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking
statements. These statements include those related to the
timing of Calithera’s clinical trials, the clinical and commercial
potential of its product candidates, Calithera’s ability to fund
its clinical programs, and Calithera’s receipt of clinical data
from its clinical trials. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking
statements. The potential product candidates that Calithera
develops may not progress through clinical development or receive
required regulatory approvals within expected timelines or at
all. In addition, clinical trials may not confirm any safety,
potency or other product characteristics described or assumed in
this press release. Such product candidates may not be beneficial
to patients or successfully commercialized. The failure to
meet expectations with respect to any of the foregoing matters may
have a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
Contact:Jennifer
McNealeyir@Calithera.com 650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2024 to May 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From May 2023 to May 2024